PhaseV Raises $15 Million in Funding to Streamline Clinical Trial Design with Machine Learning

Published: October 2023

On 24 October 2023, PhaseV, a pioneer in machine learning technology that optimizes clinical trial design and analysis, announced that the company has raised $15 million in funding from Viola Ventures, Exor Ventures, LionBird and a group of prominent angel investors. PhaseV plans to use the proceeds in expansion its offerings and global reach.

PhaseV leverages its proprietary machine learning technology for retrospectively analyzing and optimally designing clinical trials, as well as adapting in real-time throughout the trial. This machine learning driven adaptive process is likely to significantly accelerate the clinical drug development process, resulting in more efficient, targeted, and ultimately more successful clinical trials. PhaseV plans to advance paradigm shifts in the clinical trial world in order to bring new treatments to more patients, in a more precise and efficient way.

According to Roots Analysis, the clinical trial design market is estimated to be worth $441 million in 2021 and is expected to grow at CAGR of 8% during the forecast period.

For detailed insights about this domain, check out our report on Clinical Trial Design Market or email sales@rootsanalysis.com

You may also be interested in the following titles:

MEDIA CITATIONS

With the wearable device market expected to provide a smart and straightforward drug delivery experience to patient populations worldwide..

Driven by the Growing Demand for Biologics, the Biopharmaceutical Contract Manufacturing Market is Expected to Grow at an Annualized Rate of 8.1%..

A new analysis by Roots Analysis has predicted that the antibody drug conjugates (ADC) market will be worth more than $15 billion by 2030, growing at a compound annual growth rate (CAGR) of over 20 percent due to their growing popularity and therapeu..

For kidneys, Roots Analysis, a medical-technology consultancy, reckons that should be possible in about six yearsâ€™ time. Livers, which have a natural tendency to regenerate anyway, should also arrive reasonably soon. Hearts, with their complex inte..

Roots Analysis predicts the gene therapy market as a whole to reach ~$11 bln by 2025..

Roots Analysis, a market research and consulting firm for the pharmaceutical industry, says that growth will add to the estimated â€œcurrent global contract pharmaceutical installed manufacturing capacity of 125 million liters [30.4 million U.S. gall..

There are few companies with the capability to commercially manufacture viral vectors; most of the 24 firms identified by Roots Analysis in a 2016 report are CDMOs...

Roots Analysis estimates there are over 500 gene therapy candidates in clinical development, with approximately 1,700 clinical studies underway around the world...

We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry

PhaseV Raises $15 Million in Funding to Streamline Clinical Trial Design with Machine Learning

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights

Market Insights Reports

Indication Specific Reports

Who we are

Our Team

FAQ's

PhaseV Raises $15 Million in Funding to Streamline Clinical Trial Design with Machine Learning

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights